STOCK TITAN

Institutional Investor Wellington Holds 5.8M CRNX Shares (6.2%)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management reporting persons disclose beneficial ownership of 5,807,308 shares of Crinetics Pharmaceuticals common stock, representing 6.2% of the class. The stake is reported across multiple Wellington entities (holding companies and investment advisers) and is held of record by clients of the Wellington investment advisers.

The filing shows no sole voting or dispositive power reported by the filers and reports shared voting power and shared dispositive power across the Wellington entities. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control.

Positive

  • Institutional ownership of 5,807,308 shares (6.2%) demonstrates meaningful investor interest in CRNX
  • Holdings are held in the ordinary course of business, with filers certifying they are not seeking to change control

Negative

  • None.

Insights

TL;DR: An institutional investor group reports a passive, >5% position in CRNX (5.8M shares), indicating meaningful institutional interest.

Wellingtons collective ownership of 5,807,308 shares (6.2%) is a material, yet passive, holding and is recorded as owned of record by clients of its investment advisers. The absence of sole voting or dispositive power and the certification that holdings are in the ordinary course suggest this is not an activist or control-seeking position. For investors, this signals significant institutional conviction without immediate governance changes.

TL;DR: Multiple Wellington entities report shared voting/dispositive authority; the filing reflects coordinated reporting, not control intent.

The Schedule 13G discloses the structure of ownership across holding companies and investment-adviser entities, with several entities classified as HC (holding company) and at least one as IA (investment adviser). Reported shared voting and dispositive power—rather than sole control—combined with the ordinary-course certification, indicate reporting for regulatory transparency rather than a governance change. The filing clarifies which Wellington entities hold economic and voting interests.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025

FAQ

How many Crinetics (CRNX) shares does Wellington report owning?

Wellington reporting persons collectively disclose 5,807,308 shares, representing 6.2% of the class.

Does Wellington claim voting or dispositive control over CRNX shares?

The filers report 0 sole voting power and 0 sole dispositive power, with shared voting and shared dispositive power reported across entities.

Which Wellington entities filed the Schedule 13G for CRNX?

The filing lists Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP as reporting persons.

Are the reported CRNX shares held for Wellington clients or the firms themselves?

The securities are held of record by clients of the Wellington investment advisers, not directly by the reporting firms.

Is Wellington seeking to influence control of Crinetics (CRNX)?

The filers certify the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control.